MARKET

RPRX

RPRX

Royalty Pharma Plc
NASDAQ
27.51
+0.31
+1.12%
Opening 15:05 11/05 EST
OPEN
27.12
PREV CLOSE
27.20
HIGH
27.52
LOW
26.95
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
31.66
52 WEEK LOW
25.01
MARKET CAP
16.32B
P/E (TTM)
18.29
1D
5D
1M
3M
1Y
5Y
1D
Royalty Pharma Q3 2024 Earnings Preview
Seeking Alpha · 7h ago
Insights Ahead: Royalty Pharma's Quarterly Earnings
Benzinga · 9h ago
Syndax, Royalty Pharma enter into $350M royalty funding deal
Seeking Alpha · 1d ago
Royalty Pharma enters $350M synthetic royalty funding agreement with Syndax
TipRanks · 1d ago
Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
TipRanks · 1d ago
Press Release: Royalty Pharma and Syndax -2-
Dow Jones · 1d ago
SYNDAX PHARMACEUTICALS AND ROYALTY PHARMA ENTER INTO $350 MILLION ROYALTY FUNDING AGREEMENT FOR NIKTIMVO™
Reuters · 1d ago
SYNDAX PHARMACEUTICALS INC - NIKTIMVO EXPECTED TO LAUNCH IN U.S. BY EARLY Q1 2025
Reuters · 1d ago
More
About RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Webull offers Royalty Pharma plc stock information, including NASDAQ: RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.